Welche Rolle spielt die Chirurgie bei der Therapie des Diabetes mellitus Typ 2?

Zusammenfassung

Der Diabetes mellitus Typ 2 (T2DM) ist eine chronisch progrediente Erkrankung mit hoher Inzidenz. Bei Patienten mit einem T2DM findet sich überdurchschnittlich häufig eine Adipositas, die eine wichtige Rolle bei der Entwicklung der Insulinresistenz spielt. Die Basistherapie des T2DM umfasst eine Ernährungstherapie, eine Erhöhung der körperlichen Aktivität und eine Lebensstiländerung, meist in Kombination mit einer Pharmakotherapie. Insbesondere bei adipösen Patienten mit T2DM werden jedoch die metabolischen Therapieziele durch eine fehlende signifikante Gewichtsreduktion oft nicht erreicht.

Die Pankreastransplantation spielt derzeit bei der Behandlung des T2DM nur eine untergeordnete Rolle. Die bariatrische Chirurgie gewährleistet bei der Mehrzahl der Adipösen eine langfristige signifikante Gewichtsreduktion. Bei einem hohen Prozentsatz zeigt sich im kurz- bis mittelfristigen Verlauf nach dem operativen Eingriff eine komplette Remission des T2DM. Als Ursachen werden Gewichtsverlust mit einer Erhöhung der Insulinsensitivität und die Beeinflussung verschiedener gastrointestinaler Hormone durch die Operationen diskutiert. Problematisch für die abschließende Beurteilung sind die wenigen derzeit verfügbaren Langzeitergebnisse. Die Durchführung eines bariatrischen Verfahrens sollte vor allem bei adipösen Patienten mit einem T2DM, einem BMI > 35 kg/m² und schwer kontrollierbarer diabetischer Stoffwechsellage erwogen werden. Eine Ausweitung der Indikationsstellung auf normal- bzw. nur leicht übergewichtige Patienten mit T2DM kann trotz der positiven Ergebnisse nicht uneingeschränkt empfohlen werden.

Die Erforschung der Wirkmechanismen bariatrischer Eingriffe hat zu einem tieferen Verständnis der Pathophysiologie des T2DM beigetragen. Diese Erkenntnisse könnten zukünftig als Basis für die Entwicklung weniger invasiver und pharmakologischer Therapiemöglichkeiten dienen, um somit die Behandlung des T2DM individueller gestalten und weiter verbessern zu können.

Abstract

Typ 2 diabetes mellitus (T2DM) can be regarded as a chronic and progressive disease which is rapidly increasing worldwide. There is a significant coincidence of T2DM and obesity, the latter playing a major role in the development of insulin resistance. Medical treatment comprises lifestyle counseling, weight management and an increased physical activity, frequently in combination with pharmacotherapy. However, especially in obese patients, metabolic aims are frequently not achieved which can be attributed to the lack of significant weight reduction.

Currently, pancreas transplantation plays only a minor role in the treatment of patients with T2DM. Bariatric surgery has been proven to be a safe and effective therapeutic option in obese patients that leads to a significant weight loss. Moreover, in the majority of obese diabetics, a complete or partial remission of T2DM is observed. The significant weight loss is associated with improved insulin sensitivity. There is some evidence that alterations of gut hormones play an additional role in the amelioration of T2DM. However, little is known about the long-term effect of bariatric surgery on diabetes remission. Bariatric procedures should be considered in obese patients with T2DM (BMI > 35 kg/m²) and poorly controlled metabolic status. Despite the encouraging results in normal weight or overweight patients with T2DM, surgery can not yet be recommended in these patients. Intensive research about the impact of bariatric surgery on diabetes remission offers a unique opportunity to understand pathophysiology of T2DM. Furthermore, it may help to develop less invasive interventions and to identify new therapeutic targets for the treatment of T2DM.

Schlüsselwörter

Diabetes mellitus Typ 2 - Adipositas - Transplantation - bariatrische Chirurgie

Keywords

type 2 diabetes - obesity - transplantation - bariatric surgery

• Literatur

• 1 Abbasi F, Chu JW, Lamendola C et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes 2004; 53: 585-590
• 2 Aguirre V, Stylopoulos N, Grinbaum R et al. An endoluminal sleeve induces substantial weight loss and normalizes glucose homeostasis in rats with diet-induced obesity. Obesity (Silver Spring) 2008; 16: 2585-2592
• 3 Benedix F, Westphal S, Patschke R et al. Weight loss and changes in salivary ghrelin and adiponectin: comparison between sleeve gastrectomy and Roux-en-Y gastric bypass and gastric banding. Obes Surg 2011; 21: 616-624
• 4 Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-256.e5
• 5 Buchwald H, Estok R, Fahrbach K et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142: 621-632
• 6 Buse JB, Caprio S, Cefalu WT et al. How do we define cure of diabetes?. Diabetes Care 2009; 32: 2133-2135
• 7 Carlsson LM, Peltonen M, Ahlin S et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012; 367: 695-704
• 8 Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009; 33 (Suppl. 01) S33-40
• 9 Dixon JB, O'Brien PE, Playfair J et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299: 316-323
• 10 Dixon JB, Zimmet P, Alberti KG et al. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med 2011; 28: 628-642
• 11 Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17: 161-171
• 12 Ferrannini E, Gastaldelli A, Miyazaki Y et al. Beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005; 90: 493-500
• 13 Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2011; 8: 6-16
• 14 Horbach T, Wirth A. Pro & Kontra Bariatrische Chirurgie: Metabolische Chirurgie bei adipösen Diabetikern. Cardiovasc 2011; 3: 34-39
• 15 Inabnet 3rd WB, Winegar DA, Sherif B et al. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg 2012; 214: 550-556
• 16 Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443
• 17 Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846
• 18 Karra E, Yousseif A, Batterham RL. Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. Trends Endocrinol Metab 2010; 21: 337-344
• 19 Khuri SF, Najjar SF, Daley J et al. Comparison of surgical outcomes between teaching and nonteaching hospitals in the Department of Veterans Affairs. Ann Surg 2001; 234: 370-382
• 20 Kojima M, Hosoda H, Date Y et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660
• 21 Koopmans HS, Ferri GL, Sarson DL et al. The effects of ileal transposition and jejunoileal bypass on food intake and GI hormone levels in rats. Physiol Behav 1984; 33: 601-609
• 22 Marjanovic G, Winkler K, Schewe T et al. Metabolic surgery and remission of type 2 diabetes. Dtsch Med Wochenschr 2010; 135: 1020-1024
• 23 Mingrone G, Panunzi S, De Gaetano A et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-1585
• 24 Nauck MA, Vardarli I, Deacon CF et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia 2011; 54: 10-18
• 25 Parks DJ, Blanchard SG, Bledsoe RK et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-1368
• 26 Peterli R, Wölnerhanssen B, Peters T et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009; 250: 234-141
• 27 Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-350
• 28 Ramanan B, Gupta PK, Gupta H et al. Development and validation of a bariatric surgery mortality risk calculator. J Am Coll Surg 2012; 214: 892-900
• 29 Rodriguez-Grunert L, Galvao Neto MP, Alamo M et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 2008; 4: 55-59
• 30 Rubino F, Schauer PR, Kaplan LM et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 2010; 61: 393-411
• 31 Schauer PR, Kashyap SR, Wolski K et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-1576
• 32 Schenker P, Viebahn R. Pancreas and islet transplantation. The role in the treatment of diabetes mellitus. Chirurg 2009; 80: 422, 424-429
• 33 Sener A, Cooper M, Bartlett ST. Is there a role for pancreas transplantation in type 2 diabetes mellitus?. Transplantation 2010; 90: 121-123
• 34 Singh RP, Rogers J, Farney AC et al. Do pretransplant C-peptide levels influence outcomes in simultaneous kidney-pancreas transplantation?. Transplant Proc 2008; 40: 510-512
• 35 Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693
• 36 Sjöström L, Narbro K, Sjöström CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752
• 37 Stefater MA, Sandoval DA, Chambers AP et al. Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. Gastroenterology 2011; 141: 939-949
• 38 Strader AD, Vahl TP, Jandacek RJ et al. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 2005; 288: E447-453
• 39 Stroh C, Weiner R, Horbach T et al. New data on quality assurance in bariatric surgery in Germany. Zentralbl Chir 2013; 138: 180-188
• 40 Stroh C, Benedix F, Meyer F et al. Nutritive Defizite nach bariatrischer Chirurgie – systematische Literaturanalyse und Empfehlungen für Diagnostik und Substitution. Zentralbl Chir 2013; DOI: DOI: 10.1055/s-0032-1328594. [Epub ahead of print]
• 41 Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346
• 42 Tahrani AA, Bailey CJ, Del Prato S et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182-197
• 43 Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-177
• 44 Tschöp M, Weyer C, Tataranni PA et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-709
• 45 van den Hoek AM, Heijboer AC, Corssmit EP et al. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 2004; 53: 1949-1952
• 46 Vardanyan M, Parkin E, Gruessner C et al. Pancreas vs. islet transplantation: a call on the future. Curr Opin Organ Transplant 2010; 15: 124-130
• 47 Vestergaard ET, Gormsen LC, Jessen N et al. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes 2008; 57: 3205-3210